



- (51) **International Patent Classification:**
- | | | | | |
|------------------------------|-----------------------------|------------|--------------------------------|----|
| <i>A61K 35/17</i> (2015.01) | <i>C07K 16/28</i> (2006.01) | 62/848,961 | 16 May 2019 (16.05.2019) | US |
| <i>C12N 5/0783</i> (2010.01) | <i>C07K 16/30</i> (2006.01) | 16/445,965 | 19 June 2019 (19.06.2019) | US |
| <i>A61K 39/00</i> (2006.01) | <i>C07K 19/00</i> (2006.01) | 62/889,926 | 21 August 2019 (21.08.2019) | US |
| | | 62/891,131 | 23 August 2019 (23.08.2019) | US |
| | | 62/902,766 | 19 September 2019 (19.09.2019) | US |
| | | 62/932,587 | 08 November 2019 (08.11.2019) | US |
- (21) **International Application Number:** PCT/US2020/013099
- (22) **International Filing Date:** 10 January 2020 (10.01.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|------------------------------|----|
| 62/790,783 | 10 January 2019 (10.01.2019) | US |
| 62/799,462 | 31 January 2019 (31.01.2019) | US |
| 62/816,497 | 11 March 2019 (11.03.2019) | US |
| 62/817,322 | 12 March 2019 (12.03.2019) | US |
| 16/387,166 | 17 April 2019 (17.04.2019) | US |
| 62/846,563 | 10 May 2019 (10.05.2019) | US |
- (71) **Applicant:** INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS, LTD.; Suite # 5-204, 23 Line Tree Bay Avenue, P.O. Box 2547, Grand Cayman, KY1-1104 (KY).
- (71) **Applicant (for TT only):** INNOVATIVE CELLULAR THERAPEUTICS INC. [US/US]; 1405 Research Boulevard, Suite 210, Rockville, MD 20850 (US).
- (72) **Inventors:** XIAO, Lei; Building 1, 6055 Jinhai Road, Fengxian District, Shanghai, 201203 (CN). PU, Chengfei; Building 1, 6055 Jinhai Road, Fengxian District, Shanghai, 201203 (CN). CAO, Zhiyuan; Building 1, 6055 Jinhai Road, Fengxian District, Shanghai, 201203 (CN). SUN, He;


(54) **Title:** MODIFIED CELL EXPANSION AND USES THEREOF

FIG. 61

(57) **Abstract:** The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance *in vivo* and/or *in vitro*. For example, a method of enhancing T cell-based therapy comprises administering a mixed population of T cells comprising modified T cells comprising a first chimeric antigen receptor (CAR) and modified T cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.

[Continued on next page]

Building 1, 6055 Jinhai Road, Fengxian District, Shanghai,
201203 (CN). **TIAN, Le**; 1405 Research Boulevard, Suite
210, Rockville, MD 20850 (US).

(74) **Agent: TENG, Sally** et al.; Lee & Hayes, P.C., 601 West
Riverside Avenue, Suite 1400, Spokane, WA 99201 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*